{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:31:17Z","timestamp":1761989477348,"version":"3.37.3"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"25","funder":[{"DOI":"10.13039\/100009860","name":"Ramaciotti Foundations","doi-asserted-by":"crossref","award":["HIG2015\/090"],"award-info":[{"award-number":["HIG2015\/090"]}],"id":[{"id":"10.13039\/100009860","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"crossref","award":["14CDF117"],"award-info":[{"award-number":["14CDF117"]}],"id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001081","name":"Hunter Medical Research Institute","doi-asserted-by":"crossref","award":["17-10"],"award-info":[{"award-number":["17-10"]}],"id":[{"id":"10.13039\/501100001081","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1097\/md.0000000000020705","type":"journal-article","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T13:01:04Z","timestamp":1592571664000},"page":"e20705","source":"Crossref","is-referenced-by-count":4,"title":["Pilot early phase II study of decitabine and carboplatin in patients with advanced melanoma"],"prefix":"10.1097","volume":"99","author":[{"given":"Andre","family":"van der Westhuizen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Knoblauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moira C.","family":"Graves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo E.","family":"Vilain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikola A.","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,6,19]]},"reference":[{"key":"R1-20210309","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"R2-20210309","doi-asserted-by":"crossref","first-page":"e70424","DOI":"10.1371\/journal.pone.0070424","article-title":"Regulators of global genome repair do not respond to DNA damaging therapy but correlate with survival in melanoma","volume":"8","author":"Bowden","year":"2013","journal-title":"PLoS One"},{"key":"R3-20210309","doi-asserted-by":"crossref","first-page":"7918","DOI":"10.1158\/0008-5472.CAN-10-0161","article-title":"Nucleotide excision repair gene expression after Cisplatin treatment in melanoma","volume":"70","author":"Bowden","year":"2010","journal-title":"Cancer Res"},{"key":"R4-20210309","doi-asserted-by":"crossref","first-page":"60940","DOI":"10.18632\/oncotarget.10902","article-title":"Repair of UVB-induced DNA damage is reduced in melanoma due to low XPC and global genome repair","volume":"7","author":"Budden","year":"2016","journal-title":"Oncotarget"},{"key":"R5-20210309","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12885-018-4010-9","article-title":"Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma","volume":"18","author":"Budden","year":"2018","journal-title":"BMC Cancer"},{"key":"R6-20210309","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1002\/cncr.25204","article-title":"A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer","volume":"116","author":"Fang","year":"2010","journal-title":"Cancer"},{"key":"R7-20210309","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1158\/0008-5472.CAN-11-3909","article-title":"Epigenetic resensitization to platinum in ovarian cancer","volume":"72","author":"Matei","year":"2012","journal-title":"Cancer Res"},{"key":"R8-20210309","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1200\/JCO.2012.42.1529","article-title":"Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma","volume":"31","author":"Flaherty","year":"2013","journal-title":"J Clin Oncol"},{"key":"R9-20210309","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020705","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:25:50Z","timestamp":1620962750000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,19]]},"references-count":9,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000020705","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2020,6,19]]}}}